What are the commonly prescribed combined oral contraceptive pills and their typical doses?

Common Combined Oral Contraceptive Pills and Typical Doses

Start with a low-dose combined oral contraceptive containing 30-35 μg ethinyl estradiol combined with levonorgestrel or norethindrone as first-line therapy. These formulations provide optimal balance of efficacy, safety (lowest VTE risk), and tolerability while being widely available 1, 2.

First-Line Formulations

The most commonly prescribed and recommended OCPs contain:

Estrogen Component:

• Ethinyl estradiol (EE) 30-35 μg - This is the standard first-line dose 1, 2
• Lower doses (20 μg EE) are available but associated with higher breakthrough bleeding and discontinuation rates 3
• Pills with ≤35 μg EE are considered "low-dose" and comprise the majority of current prescriptions 4

Progestin Component (Second-Generation - Preferred):

• Levonorgestrel - Most commonly used, lowest VTE risk 5, 2, 6
• Norethindrone - Second most common, comparable safety profile 1, 2, 6

These second-generation progestins combined with 30-35 μg EE have the lowest thrombotic risk compared to third-generation (desogestrel, gestodene) and fourth-generation (drospirenone) progestins, which carry 1.5-2 times higher VTE risk at equivalent estrogen doses 5.

Dosing Regimens

Standard Cyclic Regimen (Most Common):

• 21-24 days of active hormone pills
• Followed by 4-7 days of placebo/hormone-free interval
• This represents 88% of current OCP use 6

Monophasic vs. Multiphasic:

• Monophasic (same hormone dose daily) - 67% of users, simpler and preferred 4, 6
• Multiphasic (varying doses) - 33% of users, no clear advantage 6

Alternative Formulations

Lower Dose Options (20 μg EE):

• Combined with levonorgestrel or other progestins
• Use when 30-35 μg causes unacceptable side effects
• Caveat: Higher breakthrough bleeding rates may lead to discontinuation and subsequent unintended pregnancy 3

Newer Estrogen Formulations:

• Estradiol valerate (1-3 mg) - available but Phase IV data still needed 4, 5
• 17β-estradiol (1.5 mg) - newer option, limited long-term data 4, 5

Third/Fourth Generation Progestins:

• Norgestimate - 32% of U.S. users 6
• Desogestrel, gestodene, drospirenone
• Use only when second-generation progestins are not tolerated due to higher VTE risk 5

Practical Prescribing Algorithm

1. Default prescription: 30-35 μg EE + levonorgestrel or norethindrone, monophasic, 21/7 regimen
2. If breakthrough bleeding persists: Ensure compliance first, then consider switching brands (bioavailability differences exist) 3
3. If androgenic side effects: Consider norgestimate or third-generation progestin (accept higher VTE risk) 4
4. If standard dose not tolerated: Step down to 20 μg EE formulation, counsel about breakthrough bleeding 3

Critical Safety Considerations

Absolute contraindications include: uncontrolled hypertension (≥160/100), active VTE or thrombophilia, migraine with aura, current breast cancer, severe liver disease, and smoking in women ≥35 years 1.

VTE risk hierarchy (from lowest to highest):

1. Second-generation progestins (levonorgestrel, norethindrone) with 30-35 μg EE
2. Third-generation progestins with 30 μg EE
3. Drospirenone or cyproterone acetate with 30 μg EE
4. Higher estrogen doses (50 μg) - rarely used 5

Initiation Protocol

Start OCPs anytime if reasonably certain patient is not pregnant 7, 8:

• Within 5 days of menses: No backup contraception needed
• After 5 days of menses: Use backup method (condoms/abstinence) for 7 days 7
• Required exam: Blood pressure measurement only; pelvic exam NOT required 1

The evidence strongly supports using the lowest effective hormone doses with second-generation progestins to minimize thrombotic risk while maintaining contraceptive efficacy and cycle control 5, 2.